Patents by Inventor Paresma R. Patel
Paresma R. Patel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11753408Abstract: Disclosed are compounds of formula (I) and formula (II): wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.Type: GrantFiled: April 22, 2021Date of Patent: September 12, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Loyola University of ChicagoInventors: Wenwei Huang, Hao Li, Wei Sun, Xiuli Huang, Paresma R. Patel, Hangmao Sun, Wei Zheng, Xiao Lu, Philip E. Sanderson, Myunghoon Kim, Meghan J. Orr, Gregory J. Tawa, Kim C. Williamson
-
Publication number: 20210246137Abstract: Disclosed are compounds of formula (I) and formula (II): wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.Type: ApplicationFiled: April 22, 2021Publication date: August 12, 2021Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, Loyola University of ChicagoInventors: Wenwei Huang, Hao Li, Wei Sun, Xiuli Huang, Paresma R. Patel, Hangmao Sun, Wei Zheng, Xiao Lu, Philip E. Sanderson, Myunghoon Kim, Meghan J. Orr, Gregory J. Tawa, Kim C. Williamson
-
Patent number: 10988472Abstract: Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.Type: GrantFiled: October 13, 2017Date of Patent: April 27, 2021Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Loyola University of ChicagoInventors: Wenwei Huang, Hao Li, Wei Sun, Xiuli Huang, Paresma R. Patel, Hangmao Sun, Wei Zheng, Xiao Lu, Philip E. Sanderson, Myunghoon Kim, Meghan J. Orr, Gregory J. Tawa, Kim C. Williamson
-
Patent number: 10513521Abstract: The present invention provides bicyclic heteroaryl inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. Exemplary compounds include those of Formula I: These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.Type: GrantFiled: July 14, 2015Date of Patent: December 24, 2019Assignees: The Brigham and Women's Hospital, Inc., University of Houston System, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Arthur Lee, John C. McKew, Paresma R. Patel, Paul B. Yu, Agustin H. Mohedas, Philip E. Sanderson, Gregory D. Cuny, Wei Zheng, Xiuli Huang
-
Publication number: 20190315740Abstract: Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.Type: ApplicationFiled: October 13, 2017Publication date: October 17, 2019Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, Loyola University of ChicagoInventors: Wenwei Huang, Hao Li, Wei Sun, Xiuli Huang, Paresma R. Patel, Hangmao Sun, Wei Zheng, Xiao Lu, Philip E. Sanderson, Myunghoon Kim, Meghan J. Orr, Gregory J. Tawa, Kim C. Williamson
-
Patent number: 10246463Abstract: Embodiments of small molecule inhibitors of hypoxia inducible factor 1 (HIF-1) and pharmaceutical compositions thereof are disclosed. The disclosed compounds suppress HIF-1 activity by inhibiting the interaction between the HIF-1 ? subunit and transcriptional co-activator protein p300. Embodiments of methods for making and using the small molecule inhibitors are also disclosed.Type: GrantFiled: April 6, 2016Date of Patent: April 2, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Kirk R. Gustafson, Martin J. Schnermann, Susanna T. S. Chan, Paresma R. Patel, William D. Figg, James B. McMahon
-
Publication number: 20180093995Abstract: Embodiments of small molecule inhibitors of hypoxia inducible factor 1 (HIF-1) and pharmaceutical compositions thereof are disclosed. The disclosed compounds suppress HIF-1 activity by inhibiting the interaction between the HIF-1 a subunit and transcriptional co-activator protein p300. Embodiments of methods for making and using the small molecule inhibitors are also disclosed.Type: ApplicationFiled: April 6, 2016Publication date: April 5, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Kirk R. Gustafson, Martin J. Schnermann, Susanna T. S. Chan, Paresma R. Patel, William D. Figg, James B. McMahon
-
Publication number: 20170197968Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.Type: ApplicationFiled: July 14, 2015Publication date: July 13, 2017Inventors: Arthur Lee, John C. McKew, Paresma R. Patel, Paul B. Yu, Agustin H. Mohedas, Philip E. Sanderson, Gregory D. Cuny, Wei Zheng, Xiuli Huang
-
Publication number: 20100093790Abstract: Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.Type: ApplicationFiled: December 16, 2009Publication date: April 15, 2010Applicant: AERIE PHARMACEUTICALS, INC.Inventors: Mitchell A. deLong, Marcos L. Sznaidman, Robert H. Oakley, Allen E. Eckhardt, Christine Hudson, Jeffrey D. Yingling, Michael Peel, Thomas E. Richardson, Clare Louise Murray, Byappanahally N. Narasinga Rao, Brian H. Heasley, Paresma R. Patel
-
Publication number: 20090069371Abstract: Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.Type: ApplicationFiled: November 20, 2008Publication date: March 12, 2009Applicant: Aerie Pharmaceuticals, Inc.Inventors: Mitchell A. deLong, Marcos L. Sznaidman, Robert H. Oakley, Allen E. Eckhardt, Christine Hudson, Jeffrey D. Yingling, Michael Peel, Thomas E. Richardson, Clare Louise Murray, Byappanahally N. Narasinga Rao, Brian H. Heasley, Paresma R. Patel
-
Publication number: 20090004692Abstract: Methods for hydrolyzing lignocellulose are provided, comprising contacting the lignocellulose with at least one chemical treatment. Methods for pretreating a lignocellulosic material comprising contacting the material with at least one chemical are also provided. Methods for liberating a substance such as an enzyme, a pharmaceutical, or a nutraceutical from plant material are also provided. These methods are more efficient, more economical, and less toxic than current methods.Type: ApplicationFiled: June 24, 2008Publication date: January 1, 2009Applicant: Athenix CorporationInventors: Brian Vande Berg, Jill Hinson, Paresma R. Patel, Brian Carr, Nicholas B. Duck
-
Patent number: 7470787Abstract: Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.Type: GrantFiled: July 11, 2006Date of Patent: December 30, 2008Assignee: Aerie Pharmaceuticals, Inc.Inventors: Mitchell A. deLong, Marcos L. Sznaidman, Robert H. Oakley, Allen E. Eckhardt, Christine Hudson, Jeffrey D. Yingling, Michael Peel, Thomas E. Richardson, Claire Louise Murray, Byappanahally N. Narasinga Rao, Brian H. Heasley, Paresma R. Patel
-
Publication number: 20040231060Abstract: Methods for hydrolyzing lignocellulose are provided, comprising contacting the lignocellulose with at least one chemical treatment. Methods for pretreating a lignocellulosic material comprising contacting the material with at least one chemical are also provided. Methods for liberating a substance such as an enzyme, a pharmaceutical, or a nutraceutical from plant material are also provided. These methods are more efficient, more economical, and less toxic than current methods.Type: ApplicationFiled: March 5, 2004Publication date: November 25, 2004Applicant: Athenix CorporationInventors: Jill Burdette, Brian Vande Berg, Brian Carr, Nicholas B. Duck, Michael G. Koziel, Nadine Carozzi, Paresma R. Patel